SEC Comment Letter 0000000000-24-010900 to ALNYLAM PHARMACEUTICALS, INC. (ALNY)

ALNYLAM PHARMACEUTICALS, INC.
Date: Sept. 25, 2024 · CIK: 0001178670 · Accession: 0000000000-24-010900

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36407

Date

September 25, 2024

Author

Jeffrey Poulton

Form

UPLOAD

Company

ALNYLAM PHARMACEUTICALS, INC.

Letter

September 25, 2024 Jeffrey Poulton Chief Financial Officer Alnylam Pharmaceuticals, Inc. 675 West Kendall Street Henri A. Termeer Square Cambridge, MA 20142 Re:Alnylam Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 Filed February 15, 2024 File No. 001-36407 Dear Jeffrey Poulton: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

September 25, 2024
Jeffrey Poulton
Chief Financial Officer
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 20142
Re:Alnylam Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
Filed February 15, 2024
File No. 001-36407
Dear Jeffrey Poulton:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io